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Background-—Prolonged QRS duration is associated with increased mortality among heart failure patients, but race or sex
differences in QRS duration and associated effect on outcomes are unknown.
Methods and Results-—We investigated QRS duration and morphology among 2463 black and white patients with heart failure and
left ventricular ejection fraction ≤35% who underwent coronary angiography and 12-lead electrocardiography at Duke University
Hospital from 1995 through 2011. We used multivariable Cox regression models to assess the relationship between QRS duration
and all-cause mortality and investigate race-QRS and sex-QRS duration interaction. Median QRS duration was 105 ms (interquartile
range [IQR], 92–132) with variation by race and sex (P<0.001). QRS duration was longest in white men (111 ms; IQR, 98–139)
followed by white women (108 ms; IQR, 92–140), black men (100 ms; IQR, 91–120), and black women (94 ms; IQR, 86–118). Left
bundle branch block was more common in women than men (24% vs 14%) and in white (21%) versus black individuals (12%). In
black patients, there was a 16% increase in risk of mortality for every 10 ms increase in QRS duration up to 112 ms (hazard ratio,
1.16; 95% CI, 1.07, 1.25) that was not present among white patients (interaction, P=0.06).
Conclusions-—Black individuals with heart failure had a shorter QRS duration and more often had non-left bundle branch block
morphology than white patients. Women had left bundle branch block more commonly than men. Among black patients, modest QRS
prolongation was associated with increased mortality. ( J Am Heart Assoc. 2017;6:e004381. DOI: 10.1161/JAHA.116.004381.)
Key Words: heart failure • mortality • QRS • race • sex
P rolonged QRS duration (>120 ms) may be associatedwith an increased risk of sudden cardiac death and all-
cause mortality.1,2 More than 20% of individuals with reduced
left ventricular ejection fraction (LVEF) have a QRS duration
≥120 ms.2,3 QRS duration is longer in healthy men than
women4–6 and longer in healthy white individuals than
black.5,7,8 However, among patients with reduced LVEF, less
is known about race and sex differences in QRS duration and
morphology and associated outcomes.2
Cardiac resynchronization therapy (CRT) has been shown
to improve functional status, decrease hospitalizations, and
improve survival in appropriately selected patients with
heart failure (HF).9,10 Predictors of a favorable response to
CRT include female sex, nonischemic etiology of systolic
HF, left bundle branch block (LBBB) morphology, and
prolonged QRS duration.11 However, CRT is underutilized
in the overall HF population,12,13 and black individuals are
less likely to have CRT devices implanted than their white
counterparts, despite being disproportionately affected by
HF and having a higher prevalence of some factors
predicting a favorable CRT response.12,14,15 Although black
women are more likely than black men to have CRT devices
implanted, the data are conflicting as to whether women
overall have an equal likelihood of receiving a CRT device
as their male counterparts.12,16 Whether race and sex
differences in CRT are attributable, in part, to differences in
QRS duration and morphology is currently not well under-
stood.
The purpose of this study is to assess race and sex
differences in QRS duration and morphology among patients
with reduced LVEF and investigate the association of QRS
duration with mortality as a function of race and sex.
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Methods
Data Sources
Data for this analysis were abstracted and merged from 3
sources: theDukeDatabankforCardiovascularDisease (DDCD),
Duke Heart Station, and Duke Echocardiography Database. The
DDCD and its data elements have been previously described.17
Briefly, the DDCD is a single-center database established in the
1960s that collects clinical characteristics of all patients who
undergo cardiac catheterization at Duke University Medical
Center (DUMC; Durham, NC) and continues to follow these
patients for assessment of outcomes. The Duke Heart Station
and Duke Echocardiography Database store electrocardiogram
(ECG) and echocardiogram (echo) variables, respectively, on
each patient who has an ECG or echo at DUMC. The Duke
University Hospital Internal ReviewBoard approved use of these
data for the purposes of this study and waived the requirement
for informed consent.
Patient Population
We examined 92 135 cardiac catheterization procedures that
occurred at the DUMC between January 1, 1995 and
December 31, 2011. Index catheterization was determined
by taking the earliest qualifying catheterization for a given
patient. The 12-lead ECG data include computer-generated
measurements of the relevant electrocardiographic intervals
(PR, QRS, QT, and RR) as analyzed using Philips TraceMaster
ECG software (Andover, MA).4,18,19 We included ECGs within
1 month of the index cardiac catheterization, and, in the case
of multiple ECGs, we selected the one closest to the index
procedure. LVEF was determined primarily from Duke
Echocardiography Database quantification. In the case where
LVEF was not available at the time of the index catheteriza-
tion, LVEF data were obtained from the closest source within
3 months preceding and 1 month following the index
catheterization. The sources of additional LVEF data included
nuclear imaging, magnetic resonance imaging, or left ven-
triculography. Patients without LVEF assessment or QRS
interval documentation were excluded.
Only patients with LVEF ≤35% were included in the
analysis. Patients were excluded for missing data on race,
key baseline characteristics, myocardial infarction (MI) within
30 days preceding the index catheterization, or revascular-
ization within the previous 3 months. Patients with ventric-
ular pacing, an uninterpretable ECG, and those taking
flecainide or propafenone were excluded. To exclude poten-
tially erroneous QRS estimates, ECGs with QRS interval
missing or considered to be outside the range of feasible
physiological values >200 ms were excluded (Figure 1). Our
Figure 1. Flow diagram for final study population. CABG indicates coronary artery bypass graft; CHF, congestive heart failure; ECG,
electrocardiogram; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.
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analysis population consisted of 2463 patients. Patient-
reported race was classified at the time of data collection as
black or white. Patients with racial classifications other than
black or white were excluded. We repeated the primary
analysis among patients who met all the primary exclusion
criteria with the addition of those patients who had
ventricular pacing in order to account for the subset of
patients with CRT (N=2678).
Outcomes
We examined the distribution of QRS duration, the preva-
lence of LBBB, right bundle branch block (RBBB), and
intraventricular conduction delay (IVCD), and the association
between QRS duration and all-cause mortality by race and
sex. Sensitivity analyses were performed including patients
with paced rhythms, in order to assess the distribution of
QRS duration and morphology and the association between
Table 1. Baseline Characteristics by Race and Sex
Characteristics
Black White
Overall (N=932) Male (N=542) Female (N=390) Overall (N=1531) Male (N=1073) Female (N=458)
Age, y 56 (47, 66) 55 (47, 64) 58 (47, 69) 65 (56, 73) 64 (55, 73) 66 (57, 75)
Medical history
Hypertension 77.0 75.5 79.2 64.9 66.5 61.1
Diabetes mellitus 33.4 27.7 41.3 31.8 32.6 29.9
Hyperlipidemia 37.9 38.0 37.7 51.8 55.1 44.1
Atrial fibrillation 4.2 6.1 1.5 11.7 13.1 8.3
Ejection fraction 23 (16, 30) 20 (15, 30) 25 (20, 30) 25 (20, 30) 25 (20, 30) 25 (20, 30)
NYHA class
I 4.4 4.8 3.8 6.3 6.0 7.2
II 21.0 23.1 18.2 22.8 23.7 20.7
III 39.6 37.6 42.3 42.9 43.5 41.5
IV 35.0 34.5 35.6 28.0 26.8 30.6
Ischemic heart disease 35.3 36.9 33.1 62.9 69.6 47.2
MI 15.8 16.6 14.6 31.2 35.6 21.0
PCI 9.7 10.9 7.9 18.2 19.7 14.6
CABG 10.5 12.9 7.2 30.7 35.5 19.4
PVD 7.2 6.6 7.9 11.4 12.2 9.6
Cerebrovascular disease 9.7 7.7 12.3 13.6 14.4 11.8
COPD 6.2 7.6 4.4 10.0 10.6 8.5
Systolic blood pressure 135 (119, 151) 133 (118, 149) 138 (121, 155) 130 (114, 146) 129 (114, 144) 131 (115, 150)
DBP 83 (72, 94) 84 (73, 96) 81 (70, 93) 76 (66, 86) 77 (68, 87) 73 (64, 82)
Heart rate 81 (70, 94) 81 (69, 93) 83 (71, 96) 80 (68, 94) 79 (67, 92) 84 (72, 98)
BMI 28.7 (24.1, 34.3) 28.1 (24.0, 33.3) 29.4 (24.2, 35.6) 27.4 (23.9, 31.6) 27.7 (24.5, 31.7) 26.2 (22.4, 31.2)
GFR 71.2 (52.2, 88.7) 74.5 (55.2, 90.3) 68.2 (48.1, 86.1) 64.9 (48.8, 81.8) 66.2 (50.1, 83.2) 62.6 (45.6, 78.6)
Valvular heart disease 17.1 14.0 21.3 21.1 18.8 26.4
Left ventricular hypertrophy 57.7 63.2 50.3 44.8 47.7 38.3
Medications
Beta-blockers 80.2 82.8 76.4 77.7 78.0 76.9
ACE-I 82.9 84.5 80.8 77.6 78.0 76.6
ARB 15.3 15.5 15.1 18.6 17.1 22.3
ICD placement during follow-up 28.2 30.1 25.6 28.2 30.6 22.7
All values are reported as median (interquartile range) or percent. ACE-I indicates angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CABG,
coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; GFR, glomerular filtration rate; ICD, implantable cardioverter defibrillator; MI,
myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease.
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QRS duration and mortality by race. Follow-up data were
obtained by self-administered questionnaires and telephone
contact at 6 months post–index catheterization and every
year thereafter on the anniversary of the initial presenta-
tion. The National Death Index was used to determine vital
status for nonresponders.20–22 Eighty-six percent of patients
had complete follow-up for at least 1.6 years, and median
follow-up for those who survived was 6.3 years.
Statistical Analysis
We identified baseline characteristics of study subjects in
each of 4 race-sex groups (black men, white men, black
women, and white women). Median, 25th, and 75th
percentiles (interquartile range; IQR) were reported for
continuous variables and percentages were reported for
categorical variables. We used a Kruskal–Wallis test to
compare the distribution of the QRS duration across the
4 race-sex groups. We then assessed differences in the
QRS duration distribution between pair-wise comparisons
for each of the 4 race-sex groups using Wilcoxon rank-sum
tests. We also identified the distribution of black and
white subjects in 3 clinically relevant QRS duration
distributions: QRS <120 ms, QRS 120 to 149 ms, and
QRS ≥150 ms.2
We used multivariable Cox regression modeling to assess
the relationship between the QRS duration and the time from
index catheterization to all-cause mortality. One analysis of
the relationship used the QRS duration as a continuous
variable and another used QRS prolongation as a categorical
variable. QRS prolongation was defined as QRS interval
>120 ms, given that previous studies have demonstrated
worse outcomes in HF patients with QRS ≥120 ms.23–26
Covariates were prespecified based on a minimum of 10
events per variable. Based on previous research, as well as
statistical and clinical judgment, the model was adjusted for
age at catheterization, baseline glomerular filtrate rate (GFR),
New York Heart Association (NYHA) class, LVEF, Duke
coronary artery severity index,25,27 heart rate, diabetes
mellitus, peripheral vascular disease (PVD), chronic obstruc-
tive lung disease, coronary artery bypass grafting (CABG),
Figure 2. Box plots of QRS interval by race and sex. The
horizontal line marks a QRS duration of 120 ms. In the figure,
diamonds indicate the mean QRS, horizontal lines within the box
indicates the median. The box extends from the 25th to the 75th
percentile, and the vertical whiskers extend to the minimum and
maximum values, or to the 75th percentile plus 1.5 times the
distance between the 75th and 25th percentile. Open circles
indicate individual data values beyond the whiskers.
Table 2. Distribution of QRS Duration and Morphology in Primary Cohort
Characteristics
Black White
P Value*Overall (N=932) Male (N=542) Female (N=390) Overall (N=1531) Male (N=1073) Female (N=458)
QRS interval, ms
Median
(Q1, Q3)
98.0 (88.0, 119.5) 100.0 (91.0, 120.0) 94.0 (86.0, 118.0) 111.0 (97.0, 139.0) 111.0 (98.0, 139.0) 107.5 (92.0, 140.0) <0.001
QRS morphology (%)
LBBB 115 (12.3) 50 (9.2) 65 (16.7) 319 (20.8) 177 (16.5) 142 (31.0) 0.012
RBBB 14 (1.5) 13 (2.4) 1 (0.3) 48 (3.1) 42 (3.9) 6 (1.3) 0.002
IVCD 128 (13.7) 94 (17.3) 34 (8.7) 284 (18.5) 231 (21.5) 53 (11.6) <0.001
QRS category,
ms (%)
<0.001
<120 699 (75.0) 403 (74.4) 296 (75.9) 906 (59.2) 644 (60.0) 262 (57.2)
120 to 149 142 (15.2) 83 (15.3) 59 (15.1) 370 (24.2) 253 (23.6) 117 (25.6)
≥150 91 (9.8) 56 (10.3) 35 (9.0) 255 (16.7) 176 (16.4) 79 (17.3)
*Comparison between races. RBBB indicates right bundle branch block; IVCD, intraventricular conduction delay; LBBB, left bundle branch block.
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diastolic blood pressure (DBP), year of ECG, and body mass
index (BMI).
As part of the multivariable Cox regression modeling
process, linearity assumptions for the model were checked by
examining the results of cubic polynomial spline plots of the
log hazard ratio (HR) of a death against the continuous QRS
duration and each of the continuous or categorical adjustment
variables.28 Transformations were then determined for each
of the adjustment variables that had a significant nonlinear
relationship.
Multivariable Cox regression modeling was also used to
determine whether the relationship between QRS duration
and all-cause mortality depended on race or sex. Given the
lack of significance of interaction between the QRS interval
with sex, we did not further explore differences in the
relationship between QRS interval and mortality by sex.
Kaplan–Meier plots were created for all-cause mortality
stratified by race and prolonged QRS duration to illustrate the
difference in event rates across these strata. We also created
adjusted spline curves of the predicted 3-year risk of mortality
across the QRS duration for the overall population and for
each race.
All statistical tests were 2-sided, and a P value of <0.05
was considered statistically significant. Statistical analyses
were conducted at the Duke Clinical Research Institute using
SAS software (version 9.4; SAS Institute Inc., Cary, NC). The
authors had full access to the data in the study and take
responsibility for the data analysis and its integrity.
Results
Baseline Patient Characteristics
Table 1 summarizes baseline characteristics across race and
sex groups. Median age varied across groups with black
individuals younger; black men 55 (interquartile range [IQR],
47–64), white men 64 (IQR, 55–73), black women 58 (IQR, 47–
69), andwhite women 66 (IQR, 57–75). Black patients hadmore
hypertension (77.0% vs 64.9%) and left ventricular hypertrophy
(57.7% vs 44.8%) than white patients. Relative to black patients,
white patients had a higher incidence of previous MI (31.2% vs
15.8%), percutaneous coronary intervention (PCI; 18.2% vs
9.7%), and coronary artery bypass grafting (CABG; 30.7%
vs 10.5%). Black (25.6%) and white women (22.7%) were less
likely to have an implantable cardioverter defibrillator (ICD) than
black (30.1%) and white men (30.6%).
Differences in QRS Duration and Morphology by
Race and Sex
Median QRS duration was 105 ms (IQR, 92–132), and the
distribution of the QRS interval varied significantly by race and
sex (P<0.001). The median QRS interval was shortest among
black females (94.0 ms) followed by black males (100.0 ms),
white females (107.5 ms), and white males (111.0 ms;
Figure 2; Table 2). The distribution of QRS interval was similar
when including patients with paced rhythms (Table 3). Com-
parisons between each group demonstrated distributional
Table 3. Distribution of QRS Duration and Morphology Including Patients With Paced Rhythms
Characteristics
Black White
P Value*Overall (N=970) Male (N=563) Female (N=407) Overall (N=1708) Male (N=1216) Female (N=492)
QRS interval, ms
Median
(Q1, Q3)
99.0 (89.0, 123.0) 101.0 (91.0, 124.0) 94.0 (86.0, 122.0) 115.0 (98.0, 146.0) 116.0 (99.0, 146.0) 112.0 (94.5, 146.0) <0.001
QRS category,
ms (%)
<0.001
<120 702 (72.4) 401 (71.2) 301 (74.0) 916 (53.6) 652 (53.6) 264 (53.7)
120 to 149 150 (15.5) 88 (15.6) 62 (15.2) 406 (23.8) 284 (23.4) 122 (24.8)
≥150 118 (12.2) 74 (13.1) 44 (10.8) 386 (22.6) 280 (23.0) 106 (21.5)
*Comparison between races.
Table 4. Association Between QRS Duration and Mortality
Overall (N=2463) Black (N=932) White (N=1531)
Mortality association with continuous QRS duration, HR (95% CI) 1.10 (1.04, 1.15) 1.16 (1.07, 1.25) 1.05 (0.98, 1.12)
Mortality association with prolonged QRS duration, HR (95% CI) 1.08 (0.96, 1.22) 1.25 (1.01, 1.54) 1.02 (0.88, 1.17)
Association between 10-ms increments in QRS duration up to 112 ms and mortality. Hazard ratio (HR) estimates are adjusted for age at catheterization, baseline glomerular filtrate rate,
New York Heart Association class, left ventricular ejection fraction, Duke coronary artery severity index,27 heart rate, diabetes mellitus, peripheral vascular disease, chronic obstructive
lung disease, coronary artery bypass grafting, diastolic blood pressure, year of electrocardiogram, and body mass index.
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differences in the QRS interval for each pair (P<0.001), with the
exception of white males versus white females (P=0.092).
Evaluation of QRS duration across clinical cutoffs of <120, 120
to 149, and ≥150 ms showed that black HF patients were less
likely to have QRS prolongation at each interval (Table 2).
Interventricular conduction abnormalities were more com-
mon among white patients than black patients (Table 2).
LBBB was present in 20.8% of white patients and 12.3% of
black patients. Both white and black women were approx-
imately twice as likely to have LBBB as their male counter-
parts. However, RBBB and nonspecific IVCD were more
common in men than women.
Association Between QRS Duration and Mortality
by Race and Sex
One hundred fifty patients (6.1%) were excluded from the
mortality assessment because of missing data. Of the remain-
ing 2313 patients, 1301 died during follow-up. Median follow-
up of patients who survived throughout the analysis was
6.3 years for both black and white patients. The unadjusted
Kaplan–Meier mortality rate for the overall population at
14 years was 74.7%. After adjustment, black patients with a
QRS >120 ms had a 25% higher risk of mortality than black
patients with a QRS <120 ms. White patients with a QRS
>120 ms had a 2% higher risk of mortality than white patients
with a QRS duration <120 ms (Table 4; Figure 3).
In the overall population, the relationship between QRS
duration and mortality was nonlinear, in that the mortality risk
increased as the QRS duration increased until 112 ms. After
112 ms, the risk of mortality did not appear to change as the
QRS duration increased. After adjusting for baseline covari-
ates, every 10 ms increase in QRS duration below 112 ms
was associated with a 10% increase in risk of mortality over
the follow-up period (HR, 1.10; 95% CI, 1.04, 1.15; Table 4).
There was a nonsignificant trend in race-based, but no sex-
based, differences in the association between QRS duration
and mortality. Accounting for the race-based differences, it
was estimated that among black patients, a 10 ms increase in
the QRS duration below 112 ms was associated with a 16%
increase in risk of mortality (interaction of QRS <112 ms and
race, P=0.06). The association between progressive QRS
prolongation below 112 ms and mortality was not significant
among white patients. When analyzing the black population in
our cohort, increases in QRS duration were associated with
higher 3-year predicted mortality rates. A similar trend in
predicted mortality rates was not observed in white patients
(Figure 4B and 4C).
As a sensitivity analysis, the association between QRS
duration and mortality by race was tested in a population of
patients that included paced rhythms. The results of this
analysis did not differ significantly from the primary analysis
(Table 5).
Discussion
There are 3 important findings in our study. First, QRS
prolongation and LBBB morphology were less common
Figure 3. Adjusted mortality rates by QRS variation and race. Yellow, black individuals QRS >120 ms;
gray, black individuals QRS ≤120 ms; orange, white individuals QRS >120 ms; blue, white individuals QRS
≤120 ms. P=0.003. P-value represents comparison across the four subgroups.
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among black HF patients than their white counterparts.
Second, LBBB was more common among women than men
independent of race. Finally, among black HF patients,
modest QRS prolongation was associated with an increase in
mortality after adjustment, whereas there was no significant
association between QRS duration and mortality among
white patients. Similarly, there were no significant sex
differences in the relationship between QRS duration and
mortality.
Differences in QRS Duration and Morphology by
Race
Our analysis found that QRS prolongation, IVCD, and LBBB
were more common among white patients than black patients
with systolic HF. These findings are consistent with previous
studies among patients with3,29 and without HF.5,7,8 One
study with 936 black, white, and Hispanic patients demon-
strated that black patients with HF were less likely to have a
Figure 4. A, Adjusted expected 3-year mortality rates for the overall
population by QRS interval. B, Adjusted expected 3-year mortality rates for
the black population by QRS interval. C, Adjusted expected 3-year mortality
rates for the white population by QRS interval. BMI indicates body mass
index; CHF_SEV, congestive heart failure severity; COPD, chronic obstruc-
tive pulmonary disease; DIASBP, diastolic blood pressure; DM_PRED,
diabetes mellitus and prediabetes; DUKEINDX PULSE, Duke coronary
artery severity index; ECGYEAR, year of electrocardiogram; EF, ejection
fraction; GFR, glomerular filtration rate; HXCABG, history of coronary artery
bypass graft; HXPVD, history of peripheral vascular disease.
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QRS >120 seconds (15.8% black, 26% white, and 25.3%
Hispanic; P=0.01).3 Hebert et al also found that LBBB
morphology was most common among Hispanic patients
(14.3%) followed by white individuals (8.8%) and black
individuals (5.8%; P=0.002). This study did not assess the
association between QRS morphology and clinical outcomes.
A retrospective analysis of the Efficacy of Vasopressin
Antagonism in Heart Failure Outcome Study with Tolvaptan
(EVEREST) trial found that QRS prolongation in a cohort of
hospitalized HF patients was more common among white
patients than black patients (P<0.01).29
Given that QRS duration >150 ms and LBBB morphology
are important in determining the eligibility for implantation of
CRT devices, differences in prevalence of conduction abnor-
mality between races may partially explain the differences in
use of CRT by race. Piccini et al found significantly lower odds
of CRT use among black patients than white patients in the
GWTG-HF registry; however, this analysis was limited by the
inability to adjust for NHYA class, QRS duration, or morphol-
ogy.12 The failure of black HF patients to meet criteria for CRT
implantation is not likely to completely explain the underuti-
lization of CRT devices in black relative to white individuals.
The following year, Farmer et al used the National Cardiovas-
cular Data Registry (NCDR) to assess ICD and CRT defibrillator
(CRT-D) use by race and found that eligible black patients had
26% lower odds of receiving CRT-D than white patients.14 The
NCDR registry captures QRS duration, morphology, NYHA
class, and duration of HF symptoms, thus increasing the
likelihood that patients included in the analysis were eligible
to receive CRT.
The presence of racial differences in QRS duration and
morphology that are evident in both healthy subjects and
patients with systolic HF indicates that these differences may
be, in part, determined through the interaction of genetic
variants, comorbidities, and environmental exposures. Several
studies have sought to identify genetic variants underlying
these racial differences. Genome-wide association studies
have identified an association between a nonsynonymous
single-nucleotide polymorphism (SNP) of the SCN10A gene
and prolonged QRS duration.30 This gene encodes a voltage-
gated sodium channel expressed in cardiac tissue. Similarly,
the SCN5A gene encodes the most common voltage-gated
sodium channel in the human heart. Investigators studied the
SCN5A gene among 4558 black patients from Jackson,
Mississippi, and found 4 SNPs associated with decreased QRS
duration and 1 SNP associated with longer QRS duration.31
Jeff et al discovered similar findings using 455 patients in the
Vanderbilt Genome-Electronic Records Project and North-
western University NUgene Project.32 These studies support
the concept that there may be a genetic component to QRS
duration that varies by self-reported race. These findings
warrant further investigation. Last, the higher prevalence of
nonischemic etiology of systolic HF in black individuals may
lend itself to lower scar burden and thus less interventricular
electrical delay relative to their white counterparts, who
exhibit a higher burden of ischemic etiology of systolic HF.
Differences in QRS Duration and Morphology by
Race and Sex
Among healthy study participants, QRS duration is longer in
men than in women.4–6 In our analysis, QRS prolongation was
more common in black men than black women, but there was
no difference between white men and women. Differences in
Figure 4. Continued
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QRS duration by both race and sex are infrequently reported.
In one of the few analyses focused on this subject, Hebert
et al found no differences in QRS duration between black men
and black women or white men and white women, though the
QRS duration was shorter in black individuals than white
individuals.3 Additionally, this analysis found no differences in
QRS duration between men and women. This cohort consisted
of patients with reduced LVEF, although the small sample size
limited the power to detect differences across subgroups. The
inadequate reporting of QRS duration by race and sex along
with the divergent findings of the available data suggest the
need for more race- and sex-balanced inclusion to determine
the true differences between populations.
Our study found that LBBB was more common for women
than men of either race. This finding is consistent with an
analysis of the Swedish Heart Failure Registry. Despite finding
that QRS duration >120 ms was more common in men than
women, Linde et al found that LBBB was more common in
women (27%) than men (24%).13 LBBB carries both therapeu-
tic and prognostic implications for HF patients, given that
those with LVEF ≤35% and LBBB morphology meet either
class I or IIa indications for CRT implantation depending on
the degree of QRS prolongation.33 A higher incidence of LBBB
morphology was also identified in women enrolled in the
SMART-AV trial34 and other observational studies.3
Association Between QRS Duration and Mortality
Among black HF patients, we found an association between
progressive QRS prolongation and mortality. However, this
association was only present up to a QRS duration of 112 ms
and was not present in white patients. Mentz et al analyzed a
population of black study participants in Jackson, Mississippi,
and found that QRS prolongation was associated with an
increased risk of mortality across all spectrums of QRS
duration.35 Similarly, progressive QRS duration is typically
associated with worse outcomes among HF patients.24,25,28
Conversely, an observational study of 3471 HF patients (56%
black, 41% white, and 3% other) found that mortality was
lowest in participants with QRS duration ≥150 ms compared
with <120 or 120 to 149 ms.2 Similarly, Linde et al found no
difference in mortality among women with LBBB compared
with women whose QRS was <120 ms.13 These inconsisten-
cies in the data highlight the complexity of the relationship
between QRS duration and mortality.
Limitations
The results of this analysis may not be representative of the
overall HF population, given that the cohort was identified
by patients undergoing cardiac catheterization. However,
this cohort is comparable with registry data of acute HF,
where over 60% of patients have an ischemic etiology of
disease.36 We were unable to screen for ICD or CRT at the
time of initial cardiac catheterization and could not reliably
determine which patients received an implantable device
after the index catheterization. Follow-up data on medication
use was also limited and unreliable, and therefore, neither
implantable device nor medication data were used in
multivariable modeling. In order to assess the true associ-
ation of QRS duration on mortality, we excluded patients
with paced rhythms. This may have excluded patients with
CRT devices that could have impacted mortality. We
performed a sensitivity analysis including individuals with
paced rhythms and RBBB and found similar results. This
analysis is subject to the limitations of retrospective cohort
studies. Although we used a multivariable model to adjust
for potential confounders, residual measured and unmea-
sured confounding may impact our findings. Finally, over
65% of patients in this data set had a QRS duration
<120 ms and 14% had a QRS duration ≥150 ms. It is
possible that there is an association between QRS prolon-
gation and mortality; however, because of low event rates
among those with wide QRS, we may be underpowered to
detect this difference.
Conclusions
In this cohort of HF patients with LVEF <35%, QRS prolongation
and LBBB was more common among white patients than black
patients and LBBB was more common among black and white
women than their male counterparts. A higher prevalence of
LBBB has important clinical implications among black andwhite
female HF patients who may preferentially benefit from CRT
Table 5. Association Between QRS Duration and Mortality Including Patients With Paced Rhythms
Overall (N=2678) Black (N=970) White (N=1708)
Mortality association with continuous QRS duration, HR (95% CI) 1.08 (1.03, 1.13) 1.15 (1.06, 1.24) 1.03 (0.97, 1.10)
Mortality association with prolonged QRS duration, HR (95% CI) 1.04 (0.93, 1.16) 1.22 (1.00, 1.49) 0.97 (0.85, 1.10)
Association between 10-ms increments in QRS duration up to 108 ms and mortality. Hazard ratio (HR) estimates are adjusted for age at catheterization, baseline glomerular filtrate rate,
New York Heart Association class, left ventricular ejection fraction, Duke coronary artery severity index,27 heart rate, diabetes mellitus, peripheral vascular disease, chronic obstructive
lung disease, coronary artery bypass grafting, diastolic blood pressure, year of electrocardiogram, and body mass index.
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compared withmenwho have systolic HF. Finally, we found that
QRS duration was not associated with mortality among white
patients, but modest QRS prolongation was associated with
increased mortality among black HF patients.
Sources of Funding
This study was supported by the Boston Scientific-Duke
STrategic Alliance for Research (BD-STAR). Dr Randolph was
supported by NIH Postdoctoral Training in Cardiovascular
Clinical Research Grant No. T32 HL 69749-11 A1.
Disclosures
Dr Thomas reported consultant and grant support from
Boston Scientific. Dr Kutyifa reported grant support from
Boston Scientific and Zoll.
References
1. Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M,
Campana C, Perini G, Deorsola A, Masotti G, Tavazzi L, Maggioni AP; Italian
Network on Congestive Heart Failure I. Left bundle-branch block is associated
with increased 1-year sudden and total mortality rate in 5517 outpatients with
congestive heart failure: a report from the Italian Network on Congestive Heart
Failure. Am Heart J. 2002;143:398–405.
2. Shenkman HJ, Pampati V, Khandelwal AK, McKinnon J, Nori D, Kaatz S,
Sandberg KR, McCullough PA. Congestive heart failure and QRS duration:
establishing prognosis study. Chest. 2002;122:528–534.
3. Hebert K, Quevedo HC, Tamariz L, Dias A, Steen DL, Colombo RA, Franco E,
Neistein S, Arcement LM. Prevalence of conduction abnormalities in a systolic
heart failure population by race, ethnicity, and gender. Ann Noninvasive
Electrocardiol. 2012;17:113–122.
4. Badheka AO, Singh V, Patel NJ, Deshmukh A, Shah N, Chothani A, Mehta K,
Grover P, Savani GT, Gupta S, Rathod A, Marzouka GR, Mitrani RD, Moscucci
M, Cohen MG. QRS duration on electrocardiography and cardiovascular
mortality (from the National Health and Nutrition Examination Survey-III). Am J
Cardiol. 2013;112:671–677.
5. Ilkhanoff L, Soliman EZ, Ning H, Liu K, Lloyd-Jones DM. Factors associated with
development of prolonged QRS duration over 20 years in healthy young
adults: the Coronary Artery Risk Development in Young Adults study. J
Electrocardiol. 2012;45:178–184.
6. Aro AL, Anttonen O, Tikkanen JT, Junttila MJ, Kerola T, Rissanen HA, Reunanen
A, Huikuri HV. Intraventricular conduction delay in a standard 12-lead
electrocardiogram as a predictor of mortality in the general population. Circ
Arrhythm Electrophysiol. 2011;4:704–710.
7. Macfarlane PWMSC, Devine B, Yang TF. Effects of age, sex, and race on ECG
interval measurements. J Electrocardiol. 1994;27:14–19.
8. Walsh JA III, Prineas R, Daviglus ML, Ning H, Liu K, Lewis CE, Sidney S,
Schreiner PJ, Iribarren C, Lloyd-Jones DM. Prevalence of electrocardiographic
abnormalities in a middle-aged, biracial population: Coronary Artery Risk
Development in Young Adults study. J Electrocardiol. 2010;43:385.e381–
389.
9. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P,
DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of
Medical Therapy P, Defibrillation in Heart Failure I. Cardiac-resynchronization
therapy with or without an implantable defibrillator in advanced chronic heart
failure. N Engl J Med. 2004;350:2140–2150.
10. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA III,
Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba
W; Investigators M-CT. Cardiac-resynchronization therapy for the prevention of
heart-failure events. N Engl J Med. 2009;361:1329–1338.
11. Goldenberg I, Moss AJ, Hall WJ, Foster E, Goldberger JJ, Santucci P, Shinn
T, Solomon S, Steinberg JS, Wilber D, Barsheshet A, McNitt S, Zareba W,
Klein H; Committee M-CE. Predictors of response to cardiac resynchro-
nization therapy in the multicenter automatic defibrillator implantation trial
with cardiac resynchronization therapy (MADIT-CRT). Circulation.
2011;124:1527–1536.
12. Piccini JP, Hernandez AF, Dai D, Thomas KL, Lewis WR, Yancy CW, Peterson
ED, Fonarow GC; Get With the Guidelines Steering C, Hospitals. Use of cardiac
resynchronization therapy in patients hospitalized with heart failure. Circula-
tion. 2008;118:926–933.
13. Linde C, Stahlberg M, Benson L, Braunschweig F, Edner M, Dahlstrom U,
Alehagen U, Lund LH. Gender, underutilization of cardiac resynchronization
therapy, and prognostic impact of QRS prolongation and left bundle branch
block in heart failure. Europace. 2015;17:424–431.
14. Farmer SA, Kirkpatrick JN, Heidenreich PA, Curtis JP, Wang Y, Groeneveld PW.
Ethnic and racial disparities in cardiac resynchronization therapy. Heart
Rhythm. 2009;6:325–331.
15. Thomas KL, Hernandez AF, Dai D, Heidenreich P, Fonarow GC, Peterson ED,
Yancy CW. Association of race/ethnicity with clinical risk factors, quality of
care, and acute outcomes in patients hospitalized with heart failure. Am Heart
J. 2011;161:746–754.
16. Alaeddini J, Wood MA, Amin MS, Ellenbogen KA. Gender disparity in the use of
cardiac resynchronization therapy in the United States. Pacing Clin Electro-
physiol. 2008;31:468–472.
17. Rosati RA, McNeer JF, Starmer CF, Mittler BS, Morris JJ Jr, Wallace AG. A new
information system for medical practice. Arch Intern Med. 1975;135:1017–
1024.
18. Williams ES, Thomas KL, Broderick S, Shaw LK, Velazquez EJ, Al-Khatib SM,
Daubert JP. Race and gender variation in the QT interval and its association
with mortality in patients with coronary artery disease: results from the Duke
Databank for Cardiovascular Disease (DDCD). Am Heart J. 2012;164:434–441.
19. Holmqvist F, Thomas KL, Broderick S, Ersboll M, Singh D, Chiswell K, Shaw LK,
Hegland DD, Velazquez EJ, Daubert JP. Clinical outcome as a function of the
PR-interval-there is virtue in moderation: data from the Duke Databank for
Cardiovascular Disease. Europace. 2015;17:978–985.
20. Bart BA, Shaw LK, McCants CB Jr, Fortin DF, Lee KL, Califf RM, O’Connor CM.
Clinical determinants of mortality in patients with angiographically diagnosed
ischemic ornonischemic cardiomyopathy. J AmColl Cardiol. 1997;30:1002–1008.
21. Harris PJ, Lee KL, Harrell FE Jr, Behar VS, Rosati RA. Outcome in medically
treated coronary artery disease. Ischemic events: nonfatal infarction and
death. Circulation. 1980;62:718–726.
22. Boyle CA, Decoufle P. National sources of vital status information: extent of
coverage andpossible selectivity in reporting.AmJEpidemiol. 1990;131:160–168.
23. Baldasseroni S, Gentile A, Gorini M, Marchionni N, Marini M, Masotti G, Porcu
M, Maggioni AP; Italian Network on Congestive Heart Failure I. Intraventricular
conduction defects in patients with congestive heart failure: left but not right
bundle branch block is an independent predictor of prognosis. A report from
the Italian Network on Congestive Heart Failure (in-CHF database). Ital Heart J.
2003;4:607–613.
24. Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN; Department of
Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart F.
QRS duration and mortality in patients with congestive heart failure. Am Heart
J. 2002;143:1085–1091.
25. Shamim W, Francis DP, Yousufuddin M, Varney S, Pieopli MF, Anker SD, Coats
AJ. Intraventricular conduction delay: a prognostic marker in chronic heart
failure. Int J Cardiol. 1999;70:171–178.
26. Koga Y, Wada T, Toshima H, Akazawa K, Nose Y. Prognostic significance of
electrocardiographic findings in patients with dilated cardiomyopathy. Heart
Vessels. 1993;8:37–41.
27. Liao L, Kong DF, Shaw LK, Sketch MH Jr, Milano CA, Lee KL, Mark DB. A new
anatomic score for prognosis after cardiac catheterization in patients with
previous bypass surgery. J Am Coll Cardiol. 2005;46:1684–1692.
28. Stone CJK, Koo CY. Additive splines in statistics. In Proceedings of the
Statistical Computing Section ASA. Washington, DC; 1985;45–58.
29. Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr,
Grinfeld L, Swedberg K, Udelson JE, Cook T, Traver B, Zimmer C, Orlandi C,
Gheorghiade M. Clinical implications of QRS duration in patients hospitalized
with worsening heart failure and reduced left ventricular ejection fraction.
JAMA. 2008;299:2656–2666.
30. Sotoodehnia N, Isaacs A, de Bakker PI, Dorr M, Newton-Cheh C, Nolte IM, van
der Harst P, Muller M, Eijgelsheim M, Alonso A, Hicks AA, Padmanabhan S,
Hayward C, Smith AV, Polasek O, Giovannone S, Fu J, Magnani JW, Marciante
KD, Pfeufer A, Gharib SA, Teumer A, Li M, Bis JC, Rivadeneira F, Aspelund T,
Kottgen A, Johnson T, Rice K, Sie MP, Wang YA, Klopp N, Fuchsberger C, Wild
SH, Mateo Leach I, Estrada K, Volker U, Wright AF, Asselbergs FW, Qu J,
Chakravarti A, Sinner MF, Kors JA, Petersmann A, Harris TB, Soliman EZ,
Munroe PB, Psaty BM, Oostra BA, Cupples LA, Perz S, de Boer RA, Uitterlinden
AG, Volzke H, Spector TD, Liu FY, Boerwinkle E, Dominiczak AF, Rotter JI, van
Herpen G, Levy D, Wichmann HE, van Gilst WH, Witteman JC, Kroemer HK, Kao
DOI: 10.1161/JAHA.116.004381 Journal of the American Heart Association 10
QRS Interval by Race and Sex in HF Patients Randolph et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
WH, Heckbert SR, Meitinger T, Hofman A, Campbell H, Folsom AR, van
Veldhuisen DJ, Schwienbacher C, O’Donnell CJ, Volpato CB, Caulfield MJ,
Connell JM, Launer L, Lu X, Franke L, Fehrmann RS, te Meerman G, Groen HJ,
Weersma RK, van den Berg LH, Wijmenga C, Ophoff RA, Navis G, Rudan I,
Snieder H, Wilson JF, Pramstaller PP, Siscovick DS, Wang TJ, Gudnason V, van
Duijn CM, Felix SB, Fishman GI, Jamshidi Y, Stricker BH, Samani NJ, Kaab S,
Arking DE. Common variants in 22 loci are associated with QRS duration and
cardiac ventricular conduction. Nat Genet. 2010;42:1068–1076.
31. Jeff JM, Brown-Gentry K, BuxbaumSG,SarpongDF, TaylorHA,GeorgeAL Jr, Roden
DM, Crawford DC. SCN5A variation is associated with electrocardiographic traits
in the Jackson Heart Study. Circ Cardiovasc Genet. 2011;4:139–144.
32. Jeff JM, Ritchie MD, Denny JC, Kho AN, Ramirez AH, Crosslin D, Armstrong L,
Basford MA, Wolf WA, Pacheco JA, Chisholm RL, Roden DM, Hayes MG,
Crawford DC. Generalization of variants identified by genome-wide association
studies for electrocardiographic traits in African Americans. Ann Hum Genet.
2013;77:321–332.
33. Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NA III, Ferguson
TB Jr, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Shanker AJ,
Silka MJ, Stevenson LW, Stevenson WG, Varosy PD, Ellenbogen KA, Freedman
RA, Gettes LS, Gillinov AM, Gregoratos G, Hayes DL, Page RL, Stevenson LW,
Sweeney MO; American College of Cardiology F, American Heart Association
Task Force on Practice G, Heart Rhythm S. 2012 ACCF/AHA/HRS focused
update of the 2008 guidelines for device-based therapy of cardiac rhythm
abnormalities: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines and the Heart
Rhythm Society. [corrected. Circulation. 2012;126:1784–1800.
34. Cheng A, Gold MR, Waggoner AD, Meyer TE, Seth M, Rapkin J, Stein KM,
Ellenbogen KA. Potential mechanisms underlying the effect of gender on
response to cardiac resynchronization therapy: insights from the SMART-AV
multicenter trial. Heart Rhythm. 2012;9:736–741.
35. Mentz RJ, Greiner MA, DeVore AD, Dunlay SM, Choudhary G, Ahmad T,
Khazanie P, Randolph TC, Griswold ME, Eapen ZJ, O’Brien EC, Thomas KL,
Curtis LH, Hernandez AF. Ventricular conduction and long-term heart failure
outcomes and mortality in African Americans: insights from the Jackson Heart
Study. Circ Heart Fail. 2015;8:243–251.
36. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg
K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of
Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan I.
Effects of oral tolvaptan in patients hospitalized for worsening heart failure:
the EVEREST Outcome Trial. JAMA. 2007;297:1319–1331.
DOI: 10.1161/JAHA.116.004381 Journal of the American Heart Association 11
QRS Interval by Race and Sex in HF Patients Randolph et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
